Injectables revolutionize care for HIV, obesity, and heart health.
Long-acting injectables (LAIs) have long been established as a mainstay in the management of various psychiatric disorders, providing stability and adherence benefits over daily oral medications. But the story doesn’t end there. In recent years, LAIs are rapidly transforming treatment landscapes far beyond mental health, playing pivotal roles in HIV prevention and management, obesity treatment, and even cardiometabolic care.
HIV Prevention and Treatment: Changing the Game
Adherence to daily antiretroviral therapy (ART) remains a significant barrier for many people living with HIV. Enter LAIs: agents like cabotegravir and rilpivirine are now approved as monthly (and even bi-monthly) injections for HIV treatment. For pre-exposure prophylaxis (PrEP), cabotegravir LAI offers protection with just a bimonthly shot, reducing the need for daily pills and helping address stigma, privacy concerns, and forgetfulness.
Key Benefits:
- Improved adherence and viral suppression rates
- Reduced pill fatigue and stigma
- Enhanced patient satisfaction
Obesity Management: A Shot at Lasting Change
With the global obesity epidemic showing no signs of slowing, innovative treatments are in high demand. GLP-1 receptor agonists, such as semaglutide, initially available as weekly subcutaneous injections, have made headlines for their profound weight loss results. Now, the push is on to develop even longer acting formulations, potentially requiring monthly or even less frequent dosing.
What’s on the Horizon?
- Longer intervals: Research is underway to extend dosing intervals further.
- Combination therapies: LAIs may soon combine weight loss and cardiometabolic benefits in a single shot.
Cardiometabolic Care: Beyond Blood Sugar
Traditionally, cardiometabolic diseases have required daily pills or frequent self injection. LAIs are poised to change this paradigm. Efforts are underway to develop long-acting agents targeting cholesterol, blood pressure, and even multi risk metabolic syndrome profiles. These innovations aim to bridge the gap between efficacy and real world adherence.
Challenges and Considerations
While the promise of LAIs is undeniable, several hurdles remain:
- Injection site reactions and cost can be barriers for some patients.
- Healthcare infrastructure must adapt to manage and administer these therapies efficiently.
- Long term data on effectiveness and safety across diverse populations is still accumulating.
Looking Forward
The era of long-acting injectables is only just beginning. What started in psychiatry is now rewriting standards of care in HIV, obesity, and cardiometabolic disease, offering hope for better adherence, improved outcomes, and enhanced quality of life.
Healthcare professionals, payers, and patients alike should keep a keen eye on this dynamic field. As science progresses, LAIs are set to become an integral component in the fight against some of the most pressing health challenges of our time.
American Journal of Managed Care. (2024). Mitigating cardiometabolic risk through therapies and weight management. https://www.ajmc.com
National Institutes of Health. (2025). Safety, tolerability, and metabolic effects of long-acting injectables. https://www.nih.gov
ViiV Healthcare. (2024). Long-acting injectable HIV innovation. https://www.viivhealthcare.com
Food and Drug Administration. (2021). FDA approves Cabenuva for the treatment of HIV-1 infection. https://www.fda.gov
World Health Organization. (2022). Obesity and overweight: Key facts. https://www.who.int
Rubino, D., Abrahamsson, N., Davies, M., & et al. (2021). Effect of semaglutide on weight loss in adults with obesity. New England Journal of Medicine, 384, 989–1002. https://doi.org/10.1056/NEJMoa2032183
Bariola, N., Foster, E., & Eckhardt, B. (2023). Long-acting antiretroviral therapy in clinical practice. Clinical Infectious Diseases, 76(7), 1298–1307.
Tice, C., & Warden, B. (2023). The future of cardiometabolic management: Long-acting therapies. Journal of Cardiometabolic Health, 5(2), 44-52.
